Combined Use of Acid Fibroblast Growth Factor, Granulocyte Colony-stimulating Factor and Zinc Sulphate Accelerates Diabetic Ulcer Healing

DOI Web Site Web Site 参考文献46件
  • Lin Shaoqiang
    The Chinese-American Research Institute for Diabetic Complications Key Laboratory of Biotechnology Pharmaceutical Engineering Wenzhou Medical College
  • Xu Hengwu
    The Chinese-American Research Institute for Diabetic Complications Key Laboratory of Biotechnology Pharmaceutical Engineering Wenzhou Medical College
  • Xiao Jian
    The Chinese-American Research Institute for Diabetic Complications Key Laboratory of Biotechnology Pharmaceutical Engineering Wenzhou Medical College
  • Liu Yanlong
    The Chinese-American Research Institute for Diabetic Complications Key Laboratory of Biotechnology Pharmaceutical Engineering Wenzhou Medical College
  • Zhang Yi
    The Chinese-American Research Institute for Diabetic Complications
  • Cai Lu
    The Chinese-American Research Institute for Diabetic Complications Department of Pediatrics, the University of Louisville
  • Li Xiaokun
    The Chinese-American Research Institute for Diabetic Complications Key Laboratory of Biotechnology Pharmaceutical Engineering Wenzhou Medical College
  • Tan Yi
    The Chinese-American Research Institute for Diabetic Complications Key Laboratory of Biotechnology Pharmaceutical Engineering Wenzhou Medical College Department of Pediatrics, the University of Louisville

この論文をさがす

説明

Our previous studies demonstrated that topic application of recombinant human acid fibroblast growth factor (aFGF) significantly, but still not completely, improved in diabetic ulcer healing. To obtain a maximal therapy for diabetic ulcer healing, a combined protocol containing aFGF, anti-oxidative reagent zinc (Zn) and stem cell stimulator granulocyte colony-stimulating factor (G-CSF), i.e.: aFGF/G-CSF/zinc sulphate (ZnSO4), was explored in the present study. Diabetes was induced by a single dose of streptozotocin (STZ, 55 mg/kg) in Sprague Dawley rats, and full thickness skin wound was made in diabetic rats at 2 months after diabetes onset. Diabetic ulcer rats were treated with aFGF, G-CSF, ZnSO4, aFGF/G-CSF/ZnSO4 or vehicle control, respectively and 3, 6, 9, 12, 15, 18, 21 and 28 days later, therapeutic effects were evaluated by calculating ulcer area. On day 7, 14, 21 after treatment, rats were sacrificed to collect 2 pieces of dorsal skin from 3 different sites (wound center, edge and healed area) to perform histopathological examination. Results showed that treatment with aFGF/G-CSF/ZnSO4 significantly enhanced ulcer healing compared with single drug treatment groups at different time points. Healing times for 100% of the wound in the aFGF/G-CSF/ZnSO4 group was 20.00±1.15 days, and significantly shorter than those in single treatment groups (p<0.05). Histopathological and immunohistochemical analysis disclosed significant increases in capillary density, proliferating cells, the expression of tissue inhibitor of metalloproteinase 1 (TIMP-1) and the ratios of TIMP-1 to matrix metalloproteinase 1 (MMP-1) in aFGF/G-CSF/ZnSO4 group as compared to other single treatments. Collectively, the combinative protocol of aFGF/G-CSF/ZnSO4 significantly enhanced the therapeutic effect on diabetic ulcer wound, probably through the promotion of fibroblast proliferation and differentiation, enhancement of blood vessel regeneration, and up-regulation of TIMP-1 and down-regulation of MMP-1 expression in diabetic ulcer healing process.

収録刊行物

参考文献 (46)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ